Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study.

Constitutively active nuclear factor-κB (NF-κB) is integral to the survival of Hodgkin/Reed-Sternberg cells (H/RS) in Hodgkin Lymphoma (HL). To investigate NF-κB pathway proteins in pediatric HL, we utilized a tissue microarray compiled from 102 children enrolled in the Children's Oncology Group intermediate-risk clinical trial AHOD0031 (56 male, 78 Caucasian, median age 15y (range 1-20y), 85 nodular sclerosing subtype, 23 Epstein Barr virus (EBV) positive, 24 refractory/relapsed disease). We examined the intensity, localization, and pathway correlations of NF-κB pathway proteins (Rel-A/p65, Rel-B, c-Rel, NF-κB1, NF-κB2, IκB-α, IKK-α, IKK-β, IKK-γ/NEMO, NIK, A20), as well as their associations with EBV status and clinical outcome. NF-κB pathway proteins were overexpressed in pediatric HL patients compared to controls. Patients with EBV-tumors, or with rapid early therapy response, had tightly coordinated regulation of NF-κB pathway proteins, whereas patients with EBV+ tumors, or slow early therapy response, had little coordinated NF-κB pathway regulation. High NIK expression was associated with a slow response to therapy and decreased EFS. Elevated Rel-B, NIK and the NF-κB inhibitor A20 were associated with decreased EFS in multivariate analysis. These studies suggest a pivotal role for the NF-κB pathway in therapy response and patient survival (clinicaltrials.gov identifier: ).

[1]  R. Gascoyne,et al.  Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. , 2010, Blood.

[2]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[3]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[4]  R. Küppers,et al.  Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. , 2009, Annual review of pathology.

[5]  S. Ley,et al.  New insights into NF-kappaB regulation and function. , 2008, Trends in immunology.

[6]  C. Van Waes,et al.  Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor-κB Subunits in Head and Neck Cancer , 2008, Clinical Cancer Research.

[7]  A. Kieser,et al.  The Viral Oncoprotein LMP1 Exploits TRADD for Signaling by Masking Its Apoptotic Activity , 2008, PLoS biology.

[8]  J. Ruland,et al.  Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.

[9]  Juan F. García,et al.  Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. , 2006, Blood.

[10]  G. Khan.  Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? , 2006, Experimental hematology.

[11]  H. Stein,et al.  Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .

[12]  T. Golub,et al.  NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. , 2005, Blood.

[13]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.

[14]  H. Stein,et al.  c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis , 2004, The Journal of experimental medicine.

[15]  H. Stein,et al.  Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells , 2003, The Journal of pathology.

[16]  Clive R. Taylor,et al.  Apoptosis and Cell Cycle-related Genes and Proteins in Classical Hodgkin Lymphoma: Application of Tissue Microarray Technique , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  L. Young,et al.  Epstein–Barr virus and oncogenesis: from latent genes to tumours , 2003, Oncogene.

[18]  S. Hamilton-Dutoit,et al.  XIAP-mediated Caspase Inhibition in Hodgkin's Lymphoma–derived B Cells , 2003, The Journal of experimental medicine.

[19]  R. Siebert,et al.  Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. , 2003, Blood.

[20]  S. Kim,et al.  The Molecular Basis for the Generation of Hodgkin and Reed-Sternberg Cells in Hodgkin’s Lymphoma , 2003, International journal of hematology.

[21]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[22]  B. Aggarwal,et al.  Nuclear Transcription Factor-kappaB in Hodgkin's Disease , 2003, Leukemia & lymphoma.

[23]  T. McDonnell,et al.  BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. , 2002, Blood.

[24]  J. Teruya-Feldstein,et al.  Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.

[25]  Shigeo Mori,et al.  Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin–Reed-Sternberg cells , 2002, Oncogene.

[26]  V. Diehl,et al.  Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. , 2002, The American journal of pathology.

[27]  L. Cooper,et al.  RelB Nuclear Translocation Mediated by C-Terminal Activator Regions of Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and Its Effect on Antigen-Presenting Function in B Cells , 2002, Journal of Virology.

[28]  G. Mosialos,et al.  Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB , 1999, Oncogene.

[29]  H. Stein,et al.  Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. , 1999, Blood.

[30]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[31]  B. Dörken,et al.  Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells , 1999, Oncogene.

[32]  W. Hammerschmidt,et al.  Epstein–Barr virus‐mediated B‐cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor , 1998, The EMBO journal.

[33]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[34]  E. Kieff,et al.  The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB , 1997 .

[35]  J Zhang,et al.  Some statistical methods for multiple endpoints in clinical trials. , 1997, Controlled clinical trials.

[36]  E. Kieff,et al.  CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. , 1996, Oncogene.

[37]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[38]  R. Küppers.  Molecular biology of Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.

[39]  Ralf Küppers,et al.  The biology of Hodgkin's lymphoma , 2009, Nature Reviews Cancer.

[40]  J. Inazawa,et al.  Overexpressed NF- (cid:1) B–inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells , 2008 .

[41]  野中 瑞穂.  Aberrant NF-κB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts , 2007 .

[42]  J. Ruland,et al.  Aberrant NF- κ B Signaling in Lymphoma: Mechanisms, Consequences and Therapeutic Implications , 2006 .